Stockscreener 앱 받기
27.51
1.54%
-0.43
전일 마감가:
$27.94
열려 있는:
$28.02
하루 거래량:
638.01K
Relative Volume:
0.70
시가총액:
$1.83B
수익:
$5.79M
순이익/손실:
$-199.61M
주가수익비율:
-9.1395
EPS:
-3.01
순현금흐름:
$-188.48M
1주 성능:
-6.59%
1개월 성능:
+13.44%
6개월 성능:
+35.18%
1년 성능:
+4.01%
1일 변동 폭
$27.29
$28.14
1주일 범위
$27.29
$30.50
52주 변동 폭
$14.40
$30.50
Celldex Therapeutics Inc Stock (CLDX) Company Profile
명칭
Celldex Therapeutics Inc
전화
908-200-7500
주소
53 FRONTAGE ROAD, HAMPTON
CLDX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CLDX
Celldex Therapeutics Inc
|
27.51 | 1.86B | 5.79M | -199.61M | -188.48M | -3.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Celldex Therapeutics Inc Stock (CLDX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-21 | 개시 | Mizuho | Outperform |
| 2025-10-13 | 개시 | Barclays | Underweight |
| 2025-04-28 | 개시 | Canaccord Genuity | Buy |
| 2025-03-20 | 개시 | Morgan Stanley | Overweight |
| 2025-02-13 | 개시 | UBS | Buy |
| 2024-10-07 | 개시 | Citigroup | Buy |
| 2024-09-30 | 개시 | Goldman | Neutral |
| 2024-09-27 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2024-06-18 | 개시 | Stifel | Buy |
| 2024-06-11 | 개시 | Wolfe Research | Outperform |
| 2023-12-20 | 개시 | TD Cowen | Outperform |
| 2023-11-10 | 업그레이드 | Wells Fargo | Underweight → Equal Weight |
| 2023-08-22 | 개시 | Wells Fargo | Underweight |
| 2021-09-17 | 개시 | Jefferies | Buy |
| 2021-09-10 | 개시 | SVB Leerink | Outperform |
| 2021-07-22 | 개시 | Guggenheim | Buy |
| 2020-02-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-08-01 | 재개 | H.C. Wainwright | Buy |
| 2016-11-07 | 개시 | Aegis Capital | Buy |
| 2016-03-08 | 다운그레이드 | Jefferies | Buy → Hold |
| 2016-03-07 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2016-03-07 | 다운그레이드 | Leerink Partners | Outperform → Mkt Perform |
| 2016-03-07 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2016-03-01 | 개시 | H.C. Wainwright | Buy |
| 2015-08-11 | 재확인 | Brean Capital | Buy |
| 2015-08-11 | 재확인 | Oppenheimer | Outperform |
| 2015-08-11 | 재확인 | ROTH Capital | Buy |
| 2015-06-02 | 재확인 | WBB Securities | Strong Buy |
| 2014-11-17 | 재확인 | ROTH Capital | Buy |
| 2014-03-04 | 재확인 | Oppenheimer | Outperform |
| 2013-07-08 | 재확인 | Cantor Fitzgerald | Buy |
| 2013-03-08 | 재확인 | Cantor Fitzgerald | Buy |
| 2013-02-26 | 재확인 | Oppenheimer | Outperform |
| 2013-01-10 | 재확인 | Cantor Fitzgerald | Buy |
| 2012-10-02 | 재확인 | Oppenheimer | Outperform |
| 2012-09-14 | 재확인 | Cantor Fitzgerald | Buy |
모두보기
Celldex Therapeutics Inc 주식(CLDX)의 최신 뉴스
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Celldex Therapeutics, Inc. $CLDX Shares Sold by Redmile Group LLC - MarketBeat
HighVista Strategies LLC Purchases New Position in Celldex Therapeutics, Inc. $CLDX - MarketBeat
Celldex Therapeutics (NASDAQ:CLDX) Stock Price Down 4.5%Should You Sell? - MarketBeat
Celldex Therapeutics (CLDX) Valuation After Launching Second Global Phase 3 Program for Barzolvolimab - Sahm
Celldex Therapeutics Initiates Global Phase 3 Trial for Barzolvolimab in Cold Urticaria, Symptomatic Dermographism - marketscreener.com
Celldex initiates phase 3 trial for cold urticaria and dermographism drug - Investing.com Canada
Celldex Initiates Global Registrational Phase 3 Program Of Barzolvolimab In Cold Urticaria And Symptomatic Dermographism - TradingView
Celldex (NASDAQ: CLDX) begins Phase 3 ColdU, SD trial after positive Phase 2 - Stock Titan
19,627 Shares in Celldex Therapeutics, Inc. $CLDX Purchased by Bollard Group LLC - Defense World
Eczema Clinical Trial Pipeline Accelerates as 100+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - The Manila Times
Celldex Therapeutics (NASDAQ:CLDX) Reaches New 12-Month HighHere's Why - MarketBeat
Does Celldex Therapeutics Inc (CLDX) offer a good opportunity for investors? - setenews.com
Celldex Therapeutics stock hits 52-week high at $29.14 By Investing.com - Investing.com Nigeria
How Celldex Therapeutics Inc. (TCE2) stock stacks up against competitorsJuly 2025 Levels & Stepwise Entry and Exit Trade Signals - Newser
Can Celldex Therapeutics Inc. (TCE2) stock sustain institutional flowsInflation Watch & Consistent Return Investment Signals - Newser
Celldex Therapeutics stock hits 52-week high at $29.14 - Investing.com
Fisher Asset Management LLC Sells 49,420 Shares of Celldex Therapeutics, Inc. $CLDX - Defense World
American Century Companies Inc. Grows Position in Celldex Therapeutics, Inc. $CLDX - Defense World
Can Celldex Therapeutics Inc. (TCE2) stock sustain revenue momentumPortfolio Return Summary & Risk Adjusted Buy and Sell Alerts - Newser
Is Celldex Therapeutics Inc. (TCE2) stock testing key supportWeekly Trend Summary & Safe Capital Growth Plans - Newser
Will Celldex Therapeutics Inc. stock outperform international peersWeekly Risk Report & Stepwise Entry/Exit Trade Alerts - Newser
Imvax Gets Positive Overall Survival Data From Phase IIb GBM Asset - Citeline News & Insights
Why Celldex Therapeutics Inc. (TCE2) stock gets analyst attention2025 Key Lessons & Expert Approved Momentum Trade Ideas - Newser
Why Celldex Therapeutics Inc. (TCE2) stock is listed among top recommendationsWeekly Risk Summary & Long-Term Capital Growth Ideas - Newser
Is Celldex Therapeutics Inc. (TCE2) stock a buy during volatile marketsJuly 2025 EndofMonth & Fast Momentum Entry Tips - Newser
Evercore Healthcare Conference - marketscreener.com
Geode Capital Management LLC Has $34.05 Million Stake in Celldex Therapeutics, Inc. $CLDX - MarketBeat
Block Trades: Is Celldex Therapeutics Inc. stock supported by innovation pipelineMarket Trend Review & Short-Term Trading Opportunity Alerts - moha.gov.vn
Precision Trading with Celldex Therapeutics Inc. (CLDX) Risk Zones - news.stocktradersdaily.com
Segall Bryant & Hamill LLC Invests $7.89 Million in Celldex Therapeutics, Inc. $CLDX - MarketBeat
Celldex Therapeutics Hits Day High with Strong 7.72% Intraday Surge - Markets Mojo
Eczema Pipeline Drugs Landscape Report 2025: MOA Analysis, R&D Progress, Clinical Trial Pipeline, and Strategic Market Evolution - The Globe and Mail
How Investors May Respond To Celldex Therapeutics (CLDX) Leadership Change and Widening Third-Quarter Losses - Sahm
A look into Celldex Therapeutics Inc (CLDX)’s deeper side - Setenews
Will Celldex Therapeutics Inc. (TCE2) stock see insider accumulationDip Buying & Reliable Entry Point Alerts - newser.com
Can Celldex Therapeutics Inc. (TCE2) stock reach $200 price targetGDP Growth & Verified Trade Idea Suggestions - newser.com
Why Celldex Therapeutics Inc. stock could be next big winnerRisk Management & Reliable Entry Point Trade Alerts - newser.com
Real time social sentiment graph for Celldex Therapeutics Inc.2025 Key Lessons & High Accuracy Investment Signals - newser.com
Celldex Therapeutics Hits Day High with 9.61% Surge in Stock Price - Markets Mojo
What risks investors should watch in Celldex Therapeutics Inc. stockWeekly Gains Summary & AI Forecast for Swing Trade Picks - newser.com
Celldex Therapeutics, Inc. $CLDX Shares Bought by TSP Capital Management Group LLC - MarketBeat
Celldex Therapeutics Inc. stock momentum explained2025 Sector Review & Low Risk High Reward Ideas - newser.com
Does Celldex Therapeutics Inc. qualify in momentum factor screening - newser.com
How to use a screener to detect Celldex Therapeutics Inc. breakoutsTrade Signal Summary & Free Safe Capital Growth Stock Tips - newser.com
What’s next for Celldex Therapeutics Inc. stock price2025 Breakouts & Breakdowns & Low Risk Investment Opportunities - newser.com
What momentum shifts mean for Celldex Therapeutics Inc.2025 Institutional Moves & Safe Swing Trade Setup Alerts - newser.com
Celldex Therapeutics (CLDX): Assessing Valuation After Recent Revenue Growth and Share Price Swings - Sahm
Celldex Therapeutics Inc (CLDX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.08%
0.91%
자본화:
|
볼륨(24시간):